A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
barriers to care
community outreach
prostate cancer
qualitative study
racial disparities
treatment
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
revised:
29
03
2024
received:
06
09
2023
accepted:
12
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Despite mandated insurance coverage since 2006 and robust health infrastructure in urban settings with high concentrations of minority patients, race-based disparities in prostate cancer (PCa) treatment persist in Massachusetts. In this qualitative study, the authors sought to identify factors driving inequities in PCa treatment in Massachusetts. Four hospitals offering PCa treatment in Massachusetts were selected using a case-mix approach. Purposive sampling was used to conduct semistructured interviews with hospital stakeholders. Additional interviews were conducted with representatives from grassroots organizations providing PCa education. Two study staff coded the interviews to identify major themes and recurrent patterns. Of the 35 informants invited, 25 participated in the study. Although national disparities in PCa outcomes were readily discussed, one half of the informants were unaware that PCa disparities existed in Massachusetts. Informants and grassroots organization representatives acknowledged that patients with PCa are willing to face transportation barriers to receive treatment from trusted and accommodating institutions. Except for chief equity officers, most health care providers lacked knowledge on accessing or using metrics regarding racial disparities in cancer outcomes. Although community outreach was recognized as a potential strategy to reduce treatment disparities and engender trust, informants were often unable to provide a clear implementation plan. This statewide qualitative study builds on existing quantitative data on the nature and extent of disparities. It highlights knowledge gaps in recognizing and addressing racial disparities in PCa treatment in Massachusetts. Improved provider awareness, the use of disparity metrics, and strategic community engagement may ensure equitable access to PCa treatment. Despite mandated insurance and urban health care access, racial disparities in prostate cancer treatment persist in Massachusetts. This qualitative study revealed that, although national disparities were acknowledged, awareness about local disparities are lacking. Stakeholders highlighted the importance of ancillary services, including translators, rideshares, and navigators, in the delivery of care. In addition, whereas hospital stakeholders were aware of collected equity outcomes, they were unsure whether and who is monitoring equity metrics. Furthermore, stakeholders agreed that community outreach showed promise in ensuring equitable access to prostate cancer treatment. Nevertheless, most interviewed stakeholders lacked clear implementation plans.
Sections du résumé
BACKGROUND
BACKGROUND
Despite mandated insurance coverage since 2006 and robust health infrastructure in urban settings with high concentrations of minority patients, race-based disparities in prostate cancer (PCa) treatment persist in Massachusetts. In this qualitative study, the authors sought to identify factors driving inequities in PCa treatment in Massachusetts.
METHODS
METHODS
Four hospitals offering PCa treatment in Massachusetts were selected using a case-mix approach. Purposive sampling was used to conduct semistructured interviews with hospital stakeholders. Additional interviews were conducted with representatives from grassroots organizations providing PCa education. Two study staff coded the interviews to identify major themes and recurrent patterns.
RESULTS
RESULTS
Of the 35 informants invited, 25 participated in the study. Although national disparities in PCa outcomes were readily discussed, one half of the informants were unaware that PCa disparities existed in Massachusetts. Informants and grassroots organization representatives acknowledged that patients with PCa are willing to face transportation barriers to receive treatment from trusted and accommodating institutions. Except for chief equity officers, most health care providers lacked knowledge on accessing or using metrics regarding racial disparities in cancer outcomes. Although community outreach was recognized as a potential strategy to reduce treatment disparities and engender trust, informants were often unable to provide a clear implementation plan.
CONCLUSIONS
CONCLUSIONS
This statewide qualitative study builds on existing quantitative data on the nature and extent of disparities. It highlights knowledge gaps in recognizing and addressing racial disparities in PCa treatment in Massachusetts. Improved provider awareness, the use of disparity metrics, and strategic community engagement may ensure equitable access to PCa treatment.
PLAIN LANGUAGE SUMMARY
CONCLUSIONS
Despite mandated insurance and urban health care access, racial disparities in prostate cancer treatment persist in Massachusetts. This qualitative study revealed that, although national disparities were acknowledged, awareness about local disparities are lacking. Stakeholders highlighted the importance of ancillary services, including translators, rideshares, and navigators, in the delivery of care. In addition, whereas hospital stakeholders were aware of collected equity outcomes, they were unsure whether and who is monitoring equity metrics. Furthermore, stakeholders agreed that community outreach showed promise in ensuring equitable access to prostate cancer treatment. Nevertheless, most interviewed stakeholders lacked clear implementation plans.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : American Cancer Society and Pfizer Global Medical Grants
Informations de copyright
© 2024 American Cancer Society.
Références
Gravlee CC. How race becomes biology: embodiment of social inequality. Am J Phys Anthropol. 2009;139(1):47‐57. doi:10.1002/ajpa.20983
Leapman MS, Dinan M, Pasha S, et al. Mediators of racial disparity in the use of prostate magnetic resonance imaging among patients with prostate cancer. JAMA Oncol. 2022;8(5):687‐696. doi:10.1001/jamaoncol.2021.8116
Borno H, George DJ, Schnipper LE, Cavalli F, Cerny T, Gillessen S. All men are created equal: addressing disparities in prostate cancer Care. Am Soc Clin Oncol Educ Book. 2019(39):302‐308. doi:10.1200/edbk_238879
Friedlander DF, Trinh QD, Krasnova A, et al. Racial disparity in delivering definitive therapy for intermediate/high‐risk localized prostate cancer: the impact of facility features and socioeconomic characteristics. Eur Urol. 2018;73(3):445‐451. doi:10.1016/j.eururo.2017.07.023
Spratt DE, Chen YW, Mahal BA, et al. Individual patient data analysis of randomized clinical trials: impact of Black race on castration‐resistant prostate cancer outcomes. Eur Urol Focus. 2016;2(5):532‐539. doi:10.1016/j.euf.2016.03.010
Alkhatib K, Labban M, Briggs L, et al. Does veteran status mitigate racial disparities in prostate cancer screening? Analysis of prostate specific antigen screening patterns in the 2018 Behavioral Risk Factor Surveillance System data. J Urol. 2022;207(5):993‐1000. doi:10.1097/ju.0000000000002379
Halabi S, Dutta S, Tangen CM, et al. Overall survival of Black and White men with metastatic castration‐resistant prostate cancer treated with docetaxel. J Clin Oncol. 2019;37(5):403‐410. doi:10.1200/jco.18.01279
George DJ, Heath EI, Sartor AO, et al. Abi Race: a prospective, multicenter study of Black (B) and White (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP) [abstract]. J Clin Oncol. 2018;36(18 suppl):LBA5009. doi:10.1200/jco.2018.36.18_suppl.lba5009
Krimphove MJ, Cole AP, Fletcher SA, et al. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(1):125‐136. doi:10.1038/s41391‐018‐0083‐4
Bill‐Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932‐942. doi:10.1056/nejmoa1311593
Zumsteg ZS, Zelefsky MJ, Woo KM, et al. Unification of favourable intermediate‐, unfavourable intermediate‐, and very high‐risk stratification criteria for prostate cancer. BJU Int. 2017;120(5B):E87‐E95. doi:10.1111/bju.13903
Zumsteg ZS, Spratt DE, Pei I, et al. A New risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy. Eur Urol. 2013;64(6):895‐902. doi:10.1016/j.eururo.2013.03.033
Nguyen DD, Haeuser L, Paciotti M, et al. Systematic review of time to definitive treatment for intermediate risk and high risk prostate cancer: are delays associated with worse outcomes? J Urol. 2021;205(5):1263‐1274. doi:10.1097/ju.0000000000001601
Nguyen DD, Labban M, Briggs L, et al. Access to definitive treatment and survival for intermediate‐risk and high‐risk prostate cancer at hospital systems serving health disparity populations. Urol Oncol. 2023;41(5):252.e9‐252.e17. doi:10.1016/j.urolonc.2023.01.011
Cole AP, Herzog P, Iyer HS, et al. Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. Cancer. 2021;127(15):2714‐2723. doi:10.1002/cncr.33564
Iyer HS, Gomez SL, Chen JT, Trinh QD, Rebbeck TR. Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position. Cancer. 2021;127(14):2525‐2534. doi:10.1002/cncr.33506
Mahal BA, Aizer AA, Ziehr DR, et al. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. Prostate Cancer Prostatic Dis. 2014;17(3):273‐279. doi:10.1038/pcan.2014.23
Mahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high‐risk prostate cancer. Urol Oncol. 2014;32(8):1285‐1291. doi:10.1016/j.urolonc.2014.04.014
Mahal AR, Chavez J, Yang DD, et al. Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. Am J Clin Oncol. 2020;43(3):163‐167. doi:10.1097/coc.0000000000000588
Krimphove MJ, Fletcher SA, Cole AP, et al. Quality of care in the treatment of localized intermediate and high risk prostate cancer at minority serving hospitals. J Urol. 2019;201(4):735‐741. doi:10.1016/j.juro.2018.10.024
Cole AP, Nguyen DD, Meirkhanov A, et al. Association of care at minority‐serving vs non‐minority‐serving hospitals with use of palliative care among racial/ethnic minorities with metastatic cancer in the United States. JAMA Netw Open. 2019;2:e187633. doi:10.1001/jamanetworkopen.2018.7633
Nguyen DD, Paciotti M, Marchese M, et al. Effect of Medicaid expansion on receipt of definitive treatment and time to treatment initiation by racial and ethnic minorities and at minority‐serving hospitals: a patient‐level and facility‐level analysis of breast, colon, lung, and prostate cancer. JCO Oncol Pract. 2021;17(5):e654‐e665. doi:10.1200/op.21.00010
Hasnain‐Wynia R, Baker DW, Nerenz D, et al. Disparities in health care are driven by where minority patients seek care: examination of the Hospital Quality Alliance measures. Arch Intern Med. 2007;167(12):1233‐1239. doi:10.1001/archinte.167.12.1233
Labban M, Chen CR, Frego N, et al. Disparities in travel‐related barriers to accessing health care from the 2017 National Household Travel Survey. JAMA Netw Open. 2023;6:e2325291. doi:10.1001/jamanetworkopen.2023.25291
Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care. 1981;19(2):127‐140. doi:10.1097/00005650‐198102000‐00001
Martínez‐González NA, Plate A, Senn O, Markun S, Rosemann T, Neuner‐Jehle S. Shared decision‐making for prostate cancer screening and treatment: a systematic review of randomised controlled trials. Swiss Med Wkly. 2018;148:w14584.
Schoenfeld ER, Francis LE. Word on the street: engaging local leaders in a dialogue about prostate cancer among African Americans. Am J Mens Health. 2016;10(5):377‐388. doi:10.1177/1557988314566503
Andrade C, Menon V, Ameen S, Kumar Praharaj S. Designing and conducting knowledge, attitude, and practice surveys in psychiatry: practical guidance. Indian J Psychol Med. 2020;42(5):478‐481. doi:10.1177/0253717620946111
Blocker DE, Romocki LS, Thomas KB, et al. Knowledge, beliefs and barriers associated with prostate cancer prevention and screening behaviors among African‐American men. J Natl Med Assoc. 2006;98:1286‐1295.
Guan A, Shim JK, Allen L, et al. Factors that influence treatment decisions: a qualitative study of racially and ethnically diverse patients with low‐ and very‐low risk prostate cancer. Cancer Med. 2023;12(5):6307‐6317. doi:10.1002/cam4.5405
Ochoa‐Dominguez CY, Garrett E, Navarro S, et al. Health care experiences of Black cancer survivors: a qualitative study exploring drivers of low and high consumer assessment of healthcare providers and systems global ratings of care. Cancer. 2023;129(21):3490‐3497. doi:10.1002/cncr.34943
Kinlock BL, Parker LJ, Bowie JV, Howard DL, LaVeist TA, Thorpe RJ Jr. High levels of medical mistrust are associated with low quality of life among Black and White men with prostate cancer. Cancer Control. 2017;24(1):72‐77. doi:10.1177/107327481702400112
Nyame YA, Cooperberg MR, Cumberbatch MG, et al. Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care. Eur Urol. 2022;82(4):341‐351. doi:10.1016/j.eururo.2022.03.007
Guidry JJ, Aday LA, Zhang D, Winn RJ. Transportation as a barrier to cancer treatment. Cancer Pract. 1997;5:361‐366.
Evans SD, Williams BE. Transportation‐related barriers to care among African American women living with HIV/AIDS: “What you getting out of the cab for?” Online J Rural Urban Res. 2013;3(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624418/
Rachele JN, Kavanagh AM, Badland H, Giles‐Corti B, Washington S, Turrell G. Associations between individual socioeconomic position, neighbourhood disadvantage and transport mode: baseline results from the HABITAT multilevel study. J Epidemiol Community Health. 2015;69(12):1217‐1223. doi:10.1136/jech‐2015‐205620
Lee RJ, Sener IN. Transportation planning and quality of life: where do they intersect? Transp Policy (Oxf). 2016;48:146‐155. Accessed May 16, 2024. doi:10.1016/j.tranpol.2016.03.004
Jazowski SA, Sico IP, Lindquist JH, et al. Transportation as a barrier to colorectal cancer care. BMC Health Serv Res. 2021;21(1):332. doi:10.1186/s12913‐021‐06339‐x
Patterson RF. New Routes to Equity: The Future of Transportation in the Black Community. The Congressional Black Caucus Foundation, Inc.; 2020.
Frego N, Beatrici E, Labban M, et al. Racial disparities in prostate cancer screening: the role of shared decision making. Am J Prev Med. 2024;66(1):27‐36. doi:10.1016/j.amepre.2023.08.005
Basourakos SP, Gulati R, Vince RA Jr, et al. Harm‐to‐benefit of three decades of prostate cancer screening in Black men. NEJM Evid. 2022;1(6). doi:10.1056/efidoa2200031
Britton BV, Nagarajan N, Zogg CK, et al. Awareness of racial/ethnic disparities in surgical outcomes and care: factors affecting acknowledgment and action. Am J Surg. 2016;212(1):102‐108.e2. doi:10.1016/j.amjsurg.2015.07.022
Mendez‐Escobar E, Adegoke Tejumola M, Lee‐Parritz A, et al. Health Equity Accelerator: A Health System’s Approach. NEJM Catalyst Innovations in Care Delivery. 2022;3(3). https://catalyst.nejm.org/doi/10.1056/CAT.22.0115
McFarling UL. ‘So much more to do’: a hospital system’s campaign to confront racism—and resistance to change—makes early strides. Stat; August 25, 2022. https://www.statnews.com/2022/08/25/mass‐general‐brigham‐campaign‐confront‐racism‐early‐progress/
Carthon B, Sibold HC, Blee S, Pentz RD. Prostate cancer: community education and disparities in diagnosis and treatment. Oncologist. 2021;26(7):537‐548. Accessed May 16, 2024. doi:10.1002/onco.13749
Nyame YA, Schraidt JA, Chakoian M, et al. A patient‐centered approach to research prioritization in prostate cancer. J Urol. 2022;208(2):277‐283. Accessed May 16, 2024. doi:10.1097/ju.0000000000002694
Trinh QD, Labban M, Daniels D, Feldman. A. Empowering communities: fostering prostate cancer awareness and resilience among men of color. J Urol. Accessed May 16, 2024. doi:10.1097/JU.0000000000003931